NYSE Arca · OSTX
OS Therapies Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OSTX: Nov 13, 2026
OS Therapies Incorporated Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.21.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.10 | $-0.16 | 2 |
| Dec 2026 | $-0.17 | $-0.16 | $-0.17 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Quiver Quantitative- Fintel · May 14, 5:11 PM EDTOS Therapies (OSTX) Price Target Increased by 16.67% to 14.28The average one-year price target for OS Therapies (NYSEAM:OSTX) has been revised to $14.28 / share. This is an increase of 16.67% from the prior estimate of $12.24 dated April 25, 2026. The price target is an average of many targets provided by analysts. The
- RTTNews · Apr 30, 10:42 AM EDTOS Therapeutics: EMA Begins Rolling Review Of OST-HER2, Stock Up(RTTNews) – OS Therapies, Inc. (OSTX) said the European Medicines Agency has initiated a rolling review of its Conditional Marketing Authorization (CMA) application for OST-HER2, an immunotherapy designed to prevent or delay recurrence in patients with fully resected pulmonary me
- Fintel · Dec 15, 9:18 AM ESTD. Boral Capital Maintains OS Therapies (OSTX) Buy RecommendationFintel reports that on December 15, 2025, D. Boral Capital maintained coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 618.51% Upside
- Fintel · Nov 18, 7:04 PM ESTLake Street Maintains OS Therapies (OSTX) Buy RecommendationFintel reports that on November 18, 2025, Lake Street maintained coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 675.44% Upside
- RTTNews · Sep 30, 8:25 AM EDTOS Therapies Updates Sequence Of OST-HER2 Regulatory Submissions, Prioritizes UK MHRA MAA Submission(RTTNews) – OS Therapies issued a regulatory update on its plans for filing marketing authorizations in the United States and United Kingdom for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma.
- RTTNews · Aug 19, 9:36 AM EDTTop Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug(RTTNews) – PainReform Ltd.'s (PRFX) solar energy business unit, developing next-generation AI-driven solar analytics, DeepSolar, has been accepted into the NVIDIA Connect Program. This gives DeepSolar access to NVIDIA's AI frameworks, development tools, and engineering support t
- The Motley Fool · Aug 19, 7:04 AM EDTOs Therapies Posts Wider Loss in Q2GAAP EPS of $0.19 for Q2 2025 fell short of analyst expectations of -$0.12, reflecting sharply increased operating expenses.
- Quiver Quantitative · Jul 14, 8:21 AM EDTNew Analyst Forecast: $OSTX Given $20.0 Price TargetWe just received data on a new analyst forecast for $OSTX. Jason Kolbert from D. Boral Capital set a price target of 20.0 for OSTX.
- RTTNews · Jun 10, 6:20 PM EDTOS Therapies Taps EVERSANA To Launch First New Pediatric Osteosarcoma Treatment In 40 Years(RTTNews) – OS Therapies Inc. (OSTX), a clinical-stage biotech company focused on cancer immunotherapies and antibody-drug conjugates, has partnered with EVERSANA to support the U.S. commercialization of OST-HER2.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for OS Therapies Incorporated from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.